Abe is one of just 130 children and young adults in the U.S. (and less than 250 people worldwide) currently living with Barth syndrome, an ultra-rare, life-threatening, genetic disease. We are honored to share this family’s video highlighting their personal experience and the hope they hold for Abe’s future. Learn More...
We were honored to participate in the EveryLife Foundation’s prestigious 13th Annual Rare Disease Scientific Workshop on October 21, 2021-- the same day that we learned that the FDA had refused to review Stealth BioTherapeutics’ New Drug Application (NDA) for elamipretide in Barth syndrome. BSF’s Executive Director, Emily Milligan, gave a highly relevant and impactful 10-minute talk regarding suggestions she has resulting from our community’s experience with the regulatory process for elamipretide.
The Barth Syndrome Foundation (BSF) is deeply disappointed by the US Food and Drug Administration’s (FDA) refusal to file Stealth BioTherapeutics’ (Stealth) submission of a New Drug Application (NDA) for elamipretide as a treatment for those living with Barth syndrome.
While the decision is a setback for the Barth syndrome community, we recognize...
Barth Syndrome Foundation is a global facilitator for advancing understanding of and developing treatments for Barth syndrome.
Let's stay in touch. Sign up for our email newsletter and we'll keep you up-to-date on all the work BSF is doing. We promise to never share your e-mail address with others.
Powered by Firespring